Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry

Table 3 Utilization pattern of steroids and IL6-RAs in relation to ICU admission

Variables	Value
Average daily dose (mg dexamethasone equivalent)^a	7.50 [6, 14.1]
Low steroid dose	496 (80.8)
High steroid dose^b	118 (19.2)
Day of steroid start^c
0	384 (55.6)
1	102 (14.8)
2	37 (5.4)
3	22 (3.2)
4	24 (3.5)
After day 5	118 (17)
Tocilizumab	213 (78.3)
Tocilizumab number of doses^d
1	180 (84.5)
2	28 (13.1)
3	5 (2.3)
Sarilumab	59 (21.7)
Sarilumab number of doses^d
1	50 (84.7)
2	9 (15.3)
Day of IL6-RAs start
0	129 (39.5)
1	55 (20.3)
2	30 (11.1)
3	21 (7.8)
4	4 (1.5)
After day 5	32 (11.8)

Data presented as n (%) unless otherwise specified
IL6-RAs interleukin-6 receptor antagonists
^aThe dose was available to 614 patients. The average daily dose of steroids was calculated by averaging the daily doses received by the patients during the ICU stay
^bHigh dose was defined as > 15 mg/day of dexamethasone or dexamethasone equivalent
^cThe proportion was calculated from the number of patients who received the steroids (n = 693)
^dThe proportion was calculated from the number of patients who received IL6-R antagonists intravenous formulation (n = 272)

ISSN: 2047-783X